ProQR Therapeutics N.V. (PRQR) Getting Somewhat Positive Press Coverage, Report Shows
Headlines about ProQR Therapeutics N.V. (NASDAQ:PRQR) have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group identifies negative and positive news coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. ProQR Therapeutics N.V. earned a media sentiment score of 0.09 on Accern’s scale. Accern also gave media coverage about the biopharmaceutical company an impact score of 47.4568545542096 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Here are some of the news headlines that may have effected Accern’s analysis:
- ProQR’s QRX-421 for Usher Syndrome receives ODD from FDA and EMA (seekingalpha.com)
- ProQR’s QRX-421 Gets Orphan Drug Designation from FDA and EMA (zacks.com)
- ProQR’s Drug Candidate QRX-421 for Usher Syndrome Receives Orphan Drug Designation from FDA and EMA (finance.yahoo.com)
- ProQR Therapeutics N.V. (PRQR) Upgraded to “Sell” at ValuEngine (americanbankingnews.com)
Shares of ProQR Therapeutics N.V. (PRQR) traded up 0.476% on Thursday, hitting $5.275. The stock had a trading volume of 12,688 shares. The stock’s market cap is $127.15 million. ProQR Therapeutics N.V. has a 12 month low of $3.65 and a 12 month high of $8.70. The company has a 50 day moving average price of $5.01 and a 200-day moving average price of $4.90.
PRQR has been the topic of a number of research analyst reports. Zacks Investment Research raised ProQR Therapeutics N.V. from a “hold” rating to a “buy” rating and set a $5.25 target price on the stock in a research note on Wednesday, August 30th. ValuEngine raised ProQR Therapeutics N.V. from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st. Finally, HC Wainwright reissued a “buy” rating and issued a $40.00 target price on shares of ProQR Therapeutics N.V. in a research note on Tuesday, June 20th. One research analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the company. ProQR Therapeutics N.V. currently has a consensus rating of “Hold” and an average price target of $14.15.
ProQR Therapeutics N.V. Company Profile
ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Utilizing its RNA repair technologies, the Company is developing a pipeline in severe genetic disorders, such as cystic fibrosis (CF) and Leber’s congenital amaurosis (LCA).
Receive News & Stock Ratings for ProQR Therapeutics N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics N.V. and related stocks with our FREE daily email newsletter.